Nelson Prager, MD
Cardiovascular Disease · Aurora, CONPI 1952397895
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 709 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Abbott accounts for 73.8% of it on its own, with 26 other manufacturers making up the rest. Among cardiovascular disease clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 709 payments — averaging $22.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$12K
- Boston Scientific$1K
- Novartis$538
- Edwards Lifesciences$369
- Heartflow, Inc.$293
- Penumbra, Inc.$173
- plus $2K from 21 others
What the payments were for
- Food & beverage$16,049100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 571 | $11,837 |
| Boston Scientific | 42 | $1,192 |
| Novartis | 24 | $538 |
| Edwards Lifesciences | 2 | $369 |
| Heartflow, Inc. | 3 | $293 |
| Penumbra, Inc. | 1 | $173 |
| Cleerly, Inc. | 2 | $161 |
| Impulse Dynamics (USA) Inc. | 2 | $160 |
| Cvrx, Inc. | 1 | $146 |
| Amgen | 7 | $142 |
| Philips North America LLC | 7 | $137 |
| Pfizer | 7 | $131 |
| Sanofi-aventis U.S. LLC | 6 | $117 |
| Merck | 6 | $88 |
| Johnson & Johnson(2 entities) | 5 | $83 |
| Cardiva Medical, Inc. | 3 | $68 |
| E.r. Squibb & Sons, L.L.C. | 3 | $66 |
| Boehringer Ingelheim | 4 | $65 |
| Medtronic | 2 | $53 |
| Biosense Webster, Inc. | 3 | $51 |
| Bayer | 2 | $37 |
| Preventice Services, LLC | 1 | $36 |
| Esperion Therapeutics, Inc. | 1 | $25 |
| Siemens Medical Solutions USA, Inc. | 1 | $25 |
| Abiomed | 1 | $20 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $20 |
| AstraZeneca | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENSITE$1,739
- TACTICATH ABLATION CATHETER, SENSOR ENABLED$605
- EnSite Precision Cardiac Mapping System$483
- VIEWMATE$459
- ENSITE PRECISION$454
- Edwards SAPIEN 3 Transcatheter Heart Valve$369
- AVEIR$252
- RESONATE$245
- Indigo System$173
- FFRct$156
- Barostim Neo System$146
- OPTIMIZER SMART SYSTEM$144
- Cleerly Ischemia$140
- Cleerly Labs$140
- MitraClip$136
- GENERAL TACHY$121
- AGILIS$111
How this compares
$16,049 in reported general payments places this provider in the 90th percentile of 276 cardiovascular disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 622 | $641,957 |
| XareltoRivaroxaban | 235 | $257,425 |
| EntrestoSacubitril/Valsartan | 139 | $125,524 |
| MultaqDronedarone Hcl | 66 | $104,235 |
| Repatha SureclickEvolocumab | 76 | $55,453 |
| Praluent PenAlirocumab | 33 | $25,260 |
| FarxigaDapagliflozin Propanediol | 21 | $15,140 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 29 | $12,275 |
| Repatha SyringeEvolocumab | 14 | $9,455 |
| VascepaIcosapent Ethyl | 11 | $6,863 |
| Dofetilide | 17 | $5,806 |
| Losartan Potassium | 482 | $5,276 |
| Metoprolol Succinate | 327 | $5,056 |
| Atorvastatin Calcium | 386 | $3,842 |
| Nebivolol Hcl | 56 | $3,201 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $131 | $641,957622 claims |
| Johnson & JohnsonXarelto | $83 | $257,425235 claims |
| NovartisEntresto | $538 | $125,524139 claims |
| Sanofi-aventis U.S. LLCMultaq | $117 | $104,23566 claims |
| AstraZenecaFarxiga | $15 | $15,14021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 276 cardiovascular disease providers in Colorado.
Other cardiovascular disease in Aurora
- Payal KohliAurora$1.7M
- Marc BonacaAurora$703K
- William SauerAurora$365K
- Rhonda MiyasakaAurora$128K
- Gregory SchwartzAurora$122K
- Edward GillAurora$96K
- Joseph AdewumiAurora$61K
- Charles FuenzalidaAurora$30K
- Christina HealyAurora$25K
- Sundeep ViswanathanAurora$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.